Rani Therapeutics Holdings (RANI) Amortization of Deferred Charges (2022 - 2026)

Rani Therapeutics Holdings' Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $477000.0 for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 722.41% year-over-year to $477000.0 in Q1 2026; TTM through Mar 2026 was $626000.0, a 57.96% decrease from a year earlier, with the FY2025 full-year figure at $207000.0, down 88.56% from the prior year.
• Amortization of Deferred Charges improved to $477000.0 in Q1 2026 per RANI's latest filing, from -$1.2 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $1.6 million in Q4 2024 and bottomed at -$1.2 million in Q4 2025.
• The 5-year median for Amortization of Deferred Charges is $58000.0 (2023), against an average of $232600.0.
• Across the five-year window, Amortization of Deferred Charges surged 3394.74% in 2023 and slumped 174.62% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $745000.0 in 2022, then plunged by 173.56% to -$548000.0 in 2023, then soared by 398.36% to $1.6 million in 2024, then slumped by 174.62% to -$1.2 million in 2025, then surged by 139.1% to $477000.0 in 2026.
• Per Business Quant, the three latest RANI Amortization of Deferred Charges figures stand at $477000.0 (Q1 2026), -$1.2 million (Q4 2025), and $1.3 million (Q3 2025).